Table 5. Conclusions from Comparison of Empirical Data to Simulations of Additive Agonism for Orthosteric Ligands in Combination with ZCZ011a.
| signaling pathway | THC | CP55940 | AMB-FUBINACA |
|---|---|---|---|
| cAMP | inconsistent (negative) | – | – |
| G protein dissociation | – | inconsistent (negative) | inconsistent (negative) |
| ERK1/2 phosphorylation | inconsistent (positive) | – | not inconsistent |
| β-arrestin translocation | inconsistent (positive) | not inconsistent | not inconsistent |
| receptor trafficking | inconsistent (positive) | – | – |
a
Comparisons between empirical data and in silico simulations of additive agonism have been qualitatively classified as “not inconsistent” (could be explained by additive agonism) and “inconsistent” (negative = less-than-additive effect, positive = greater-than-additive effect).